ArticleOncotarget2016

RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.

Adrian P Wiegmans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.